Plasma levels of VEGF-C, VEGF-D, VEGFR-2 and VEGFR-3 in patients with newly diagnosed lymphomas.
- Author:
Fang LIU
1
;
Yu-Qin SONG
;
Chen ZHANG
;
Zhi-Ying FU
;
Ling-Yan PING
;
Zhi-Tao YING
;
Wen ZHENG
;
Xiao-Pei WANG
;
Yan XIE
;
Ning-Jing LIN
;
Mei-Feng TU
;
Jun ZHU
Author Information
1. Department of Hematology, Peking University Shougang Hospital, Beijing, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Aged;
Aged, 80 and over;
Female;
Humans;
Lymphoma;
blood;
diagnosis;
pathology;
Middle Aged;
Neoplasm Staging;
Prognosis;
Vascular Endothelial Growth Factor C;
blood;
Vascular Endothelial Growth Factor D;
blood;
Vascular Endothelial Growth Factor Receptor-2;
blood;
Vascular Endothelial Growth Factor Receptor-3;
blood;
Young Adult
- From:
Journal of Experimental Hematology
2011;19(5):1184-1188
- CountryChina
- Language:Chinese
-
Abstract:
The objective of this study was to detect the expression levels of VEGF-C, VEGF-D, VEGFR-2 and VEGFR-3 in plasma of newly diagnosed lymphoma patients, and analyze their possible relationships with clinicopathological characteristics and prognosis. The expression levels of VEGF-C, VEGF-D, VEGFR-2 and VEGFR-3 in plasma from 86 newly diagnosed lymphoma patients were detected by enzyme-linked immunosorbent assay (ELISA). As a results, the multivariate analysis showed that VEGF-C level in non-Hodgkin's lymphoma patients was low, but high in Hodgkin's lymphoma patients; VEGFR-2 level was higher in patients > 60 years, while VEGF-D level was lower in patients with IPI > 2. The univariate analysis showed that VEGF-D level was lower in patients with IPI > 2, while VEGF-D and VEGF-C levels were higher in patients without B symptoms. Relationship analysis between these factors indicated that the relation of VEGF-D expression level with VEGFR-2 and VEGFR-3 was positive. It is concluded that VEGF-C, VEGF-D, VEGFR-2 and VEGFR-3 play important roles in the pathogenesis of lymphoma, and may be used as indicators of prognosis evaluation or even guide for the antiangiogenesis treatment of lymphoma.
